Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5583141	AZURITY	Heterocyclic compounds and their use as angiotensin antagonists	Dec, 2013 (10 years ago)
US7157584	AZURITY	Benzimidazole derivative and use thereof	May, 2025 (1 year, 25 days from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (8 months from now)
US9066936	AZURITY	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent	Mar, 2028 (3 years from now)
US9169238	AZURITY	Solid pharmaceutical composition	Feb, 2030 (5 years from now)
US9387249	AZURITY	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone	Jul, 2031 (7 years from now)

Edarbyclor is owned by Azurity.

Edarbyclor contains Azilsartan Kamedoxomil; Chlorthalidone.

Edarbyclor has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Edarbyclor are:

Edarbyclor was authorised for market use on 20 December, 2011.

Edarbyclor is available in tablet;oral dosage forms.

Edarbyclor can be used as treatment of hypertension.

Drug patent challenges can be filed against Edarbyclor from 25 February, 2015.

The generics of Edarbyclor are possible to be released after 01 July, 2031.

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Dec 20, 2014
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;12.5MG	TABLET;ORAL	Prescription
EQ 40MG MEDOXOMIL;25MG	TABLET;ORAL	Prescription

Edarbyclor patents expiration